SanegeneBio Signs Major Global RNAi Licensing Deal with Genentech for Groundbreaking Therapies#United_States#Boston#Genentech#RNAi_Therapeutics#SanegeneBio
SanegeneBio Signs Major Global RNAi Licensing Deal with Genentech for Groundbreaking Therapies
SanegeneBio has entered into a significant global partnership with Genentech to develop RNAi therapeutics, receiving $200 million upfront and potential earnings up to $1.5 billion.
third-news.com
February 2, 2026 at 12:16 PM
SanegeneBio Signs Major Global RNAi Licensing Deal with Genentech for Groundbreaking Therapies#United_States#Boston#Genentech#RNAi_Therapeutics#SanegeneBio
Alnylam Pharmaceuticals Joins Alliance to Enhance Genomic Research and Drive Precision Medicine Forward#United_States#San_Diego#Alnylam_Pharmaceuticals#Genomic_Discovery#RNAi_Therapeutics
Alnylam Pharmaceuticals Joins Alliance to Enhance Genomic Research and Drive Precision Medicine Forward
Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery to expand the genomic dataset that supports the development of precision medicine, enhancing drug discovery capabilities.
third-news.com
September 18, 2025 at 2:41 PM
Alnylam Pharmaceuticals Joins Alliance to Enhance Genomic Research and Drive Precision Medicine Forward#United_States#San_Diego#Alnylam_Pharmaceuticals#Genomic_Discovery#RNAi_Therapeutics